Literature DB >> 33688345

The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.

Jianchun Xiao1, Li Wang1, Tao Hong1, Binglu Li1, Wei Liu1, Qiang Qu1, Chaoji Zheng1, Xiaodong He1.   

Abstract

BACKGROUND: Incidence of biliary tract cancers (BTCs) in China is high, and surgery is the only curative option. Preoperative CA19-9 has been identified as a predictor for survival in patients with resectable BTCs, but more potential predictors need to be studied. This retrospective study aimed to establish the prognostic significance of CA19-9/TBIL ratio (CTR) in patients with BTCs.
METHODS: A retrospective analysis was performed in patients who were diagnosed with BTCs and received surgical resection between 2013 and 2018 at PUMCH. Demographic and clinical parameters were collected. Preoperative CA19-9 and CTR were classified as elevated (>58.6 and >0.83) according to the receiver operating characteristic (ROC) analysis. Demographic and clinical parameters were compared between the groups using Student's t-test, chi-square, or Fisher's exact test. Survival analysis was performed by the Kaplan-Meier methods, and the relationship between variables and survival was assessed by the log-rank test. Cox regression analysis was conducted to identify potential risk factors for overall survival.
RESULTS: In total, 109 participants were involved in the final analysis. The overall survival rate was 18.0% at 5 years, with a median survival duration of 1.58 years. The Kaplan-Meier analysis indicated that higher CTR was associated with shorter OS (15 vs. 50, p < 0.01). Univariate survival analysis identified TNM staging, CA19-9, and CTR as statistically significant prognostic factors. In a multiple Cox analysis, only CTR was proved as a significantly independent prognostic factor.
CONCLUSION: CTR acts as an independent prognostic predictor for patients with biliary tract cancer.
Copyright © 2021 Jianchun Xiao et al.

Entities:  

Year:  2021        PMID: 33688345      PMCID: PMC7925024          DOI: 10.1155/2021/5829893

Source DB:  PubMed          Journal:  J Oncol        ISSN: 1687-8450            Impact factor:   4.375


  33 in total

1.  The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.

Authors:  Chang Moo Kang; Jun Young Kim; Gi Hong Choi; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee; Byong Ro Kim
Journal:  J Surg Res       Date:  2007-04-09       Impact factor: 2.192

Review 2.  Serum tumor markers in bile duct cancer--a review.

Authors:  M Grunnet; M Mau-Sørensen
Journal:  Biomarkers       Date:  2014-05-23       Impact factor: 2.658

3.  Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.

Authors:  Mie Grunnet; Ib J Christensen; Ulrik Lassen; Lars H Jensen; Magnus Lydolph; Jennifer J Knox; Mairead G McNamara; Mark Jitlal; Harpreet Wasan; John Bridgewater; Juan W Valle; Morten Mau-Sorensen
Journal:  Eur J Cancer       Date:  2015-05-09       Impact factor: 9.162

4.  Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma.

Authors:  Naru Kondo; Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Hayato Sasaki; Taijiro Sueda
Journal:  J Surg Oncol       Date:  2014-06-02       Impact factor: 3.454

5.  Epidemiology and Risk Factors of Cholangiocarcinoma.

Authors:  Martha M Kirstein; Arndt Vogel
Journal:  Visc Med       Date:  2016-12-01

6.  Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies.

Authors:  Ioannis Hatzaras; Carl Schmidt; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston
Journal:  HPB (Oxford)       Date:  2010-03       Impact factor: 3.647

7.  The reliability of highly elevated CA 19-9 levels.

Authors:  B R Osswald; F E Klee; S Wysocki
Journal:  Dis Markers       Date:  1993-12       Impact factor: 3.434

Review 8.  Advances in biomarkers of biliary tract cancers.

Authors:  Jun Hu; Baobing Yin
Journal:  Biomed Pharmacother       Date:  2016-04-16       Impact factor: 6.529

9.  The prognostic and predictive value of serum CA19.9 in pancreatic cancer.

Authors:  J L Humphris; D K Chang; A L Johns; C J Scarlett; M Pajic; M D Jones; E K Colvin; A Nagrial; V T Chin; L A Chantrill; J S Samra; A J Gill; J G Kench; N D Merrett; A Das; E A Musgrove; R L Sutherland; A V Biankin
Journal:  Ann Oncol       Date:  2012-01-11       Impact factor: 32.976

10.  Prognostic significance of and risk prediction model for lymph node metastasis in resectable intrahepatic cholangiocarcinoma: do all require lymph node dissection?

Authors:  Jonathan G Navarro; Jin Ho Lee; Incheon Kang; Seoung Yoon Rho; Gi Hong Choi; Dai Hoon Han; Kyung Sik Kim; Jin Sub Choi
Journal:  HPB (Oxford)       Date:  2020-02-08       Impact factor: 3.647

View more
  1 in total

1.  Preoperative Alkaline Phosphatase-adjusted CA19-9 as a Superior Prognosticator for Extrahepatic Biliary Tract Cancer With Jaundice.

Authors:  Shinichi Ikuta; Tsukasa Aihara; Takayoshi Nakajima; Meidai Kasai; Naoki Yamanaka
Journal:  Cancer Diagn Progn       Date:  2022-09-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.